Method and apparatus of a defined serumfree medical solution

Claim 2

The defined serumfree medical solution consisting essentially of effective amounts of: a. an aqueous nutrient and electrolyte solution; b. a glycosaminoglycan; c. a deturgescent agent; d. an energy source; e. a buffer system; f. an antioxidant; g. membrane stabilizing agents; h. an antibiotic and/or an antimycotic agent; i. ATP presursors; and j. nutrient cell supplements having improved corneal preservation upon storage as compared to the same composition not containing the (g) or (h) or (i) or (j) components.

Claim 3

The defined serumfree medical solution containing components which maintain and enhance the preservation of eye tissues, including human corneal tissues at low temperatures (2° C. to 15° C.) with a physiological pH consisting essentially of effective amounts of: a. an aqueous nutrient and electrolyte solution; b. a glycosaminoglycan; c. a deturgescent agent; d. an energy source; e. a buffer system; f. an antioxidant; g. membrane stabilizing agents; h. an antibiotic and/or an antimycotic agent; i. ATP presursors; and j. nutrient cell supplements having improved corneal preservation upon storage as compared to the same composition not containing the (g) or (h) or (i) or (j) components.

Claim 4

The defined serumfree medical solution containing components which maintain and enhance the preservation of eye tissues, including human corneal tissues at low temperatures (2° C. to 15° C.) with a physiological pH consisting essentially of effective amounts of: a. an aqueous nutrient and electrolyte solution; b. a glycosaminoglycan; c. a deturgescent agent; d. an energy source; e. a buffer system; f. an antioxidant; g. membrane stabilizing agents; h. an antibiotic and/or an antimycotic agent; i. ATP presursors; and j. nutrient cell supplements having improved corneal preservation upon storage as compared to the same composition not containing the (g) or (h) or (i) or (j) components.

Claim 5

The defined serumfree medical solution containing components which maintain and enhance the preservation of eye tissues, Including human corneal tissues at low temperatures (2° C. to 15° C.) with a physiological pH comprised of: a. An aqueous nutrient and electrolyte solution selected from the group of: 1. Eagle's minimal essential medium (MEM) 2. TC199 medium 3. A combination of Eagle's minimal essential medium (MEM) and TC199 b. A glycosaminoglycan in the range of 0.01 mg/ml to 100 mg/ml selected from the group of: 1. chondroitin sulfate; 2. dermatan sulfate; 3. dermatin sulfate; 4. heparin sulfate; 5. heparan sulfate; 6. karatin sulfate; 7. keratan sulfate; and/or 8. hyaluronic acid; c. A deturgescent agent in the range of 0.01 mg/ml to 100 mg/ml selected from the group of: 1. dextran; 2. dextran sulfate;

Claim 6

The defined serumfree medical solution containing components which maintain and enhance the preservation of eye tissues, Including human corneal tissues at low temperatures (2° C. to 15° C.) with a physiological pH comprised of: a. An aqueous nutrient and electrolyte solution selected from the group of: 1. Eagle's minimal essential medium (MEM) 2. TC199 medium 3. A combination of Eagle's minimal essential medium (MEM) and TC199 b. A glycosaminoglycan in the range of 0.01 mg/ml to 100 mg/ml selected from the group of: 1. chondroitin sulfate; 2. dermatan sulfate; 3. dermatin sulfate; 4. heparin sulfate; 5. heparan sulfate; 6. karatin sulfate; 7. keratan sulfate; and/or 8. hyaluronic acid; c. A deturgescent agent in the range of 0.01 mg/ml to 100 mg/ml selected from the group of: 1. dextran; 2. dextran sulfate;

Claim 7

polyvinyl pyrrolidone; 4. polyethylene glycol; 5. polyvinyl acetate; 6. hydroxypropylmethyl cellulose; and 7. carboxypropylmethyl cellulose; d. An energy source in a range of 0.05 mM to 10 mM selected from the group of: 1. glucose; 2. pyruvate; 3. sucrose; 4. fructose; and 5. dextrose; e. A buffer system in a range of 0.1 mM to 100 mM selected from the group of: 1. Bicarbonate buffer; and 2. HEPES buffer; f. An antioxidant in a range of 0.001 mM to 10 mM selected from the group of: 1. ascorbic acid; 2. 2-mercaptoethanol; 3. glutathione; and 4. alpha-tocopherol; g. A membrane stabilizing component in a range of 0.01 mg/ml to 500 mg/ml selected from the group of: 1. vitamin A;

Claim 8

polyvinyl pyrrolidone; 4. polyethylene glycol; 5. polyvinyl acetate; 6. hydroxypropylmethyl cellulose; and 7. carboxypropylmethyl cellulose; d. An energy source in a range of 0.05 mM to 10 mM selected from the group of: 1. glucose; 2. pyruvate; 3. sucrose; 4. fructose; and 5. dextrose; e. A buffer system in a range of 0.1 mM to 100 mM selected from the group of: 1. Bicarbonate buffer; and 2. HEPES buffer; f. An antioxidant in a range of 0.001 mM to 10 mM selected from the group of: 1. ascorbic acid; 2. 2-mercaptoethanol; 3. glutathione; and 4. alpha-tocopherol; g. A membrane stabilizing component in a range of 0.01 mg/ml to 500 mg/ml selected from the group of: 1. vitamin A;

Claim 9

vitamin B; 3. retinoic acid; 4. ethanolamine; 5. phosphoethanolamine; 6. selenium and 7. transferrin; h. An antibiotic and/or antimycotic in the range of 0.1μg/ml to 1 mg/ml selected from the group of: 1. amphotericin-B; 2. gentamycin sulfate; 3. kanamycin sulfate; 4. neomycin sulfate; 5. nystatin; 6. penicillin; 7. tobramycin; and 8. streptomycin; i. ATP presursors in a range of 0.001 mM to 10 mM selected from the group of: 1. adenosine; 2. inosine; and 3. adenine; j. Nutrient cell supplements in a range of 0.001 mM to 10 mM selected from the group of: 1. cholestrol; 2. L-hydroxyproline;

Claim 10

vitamin B; 3. retinoic acid; 4. ethanolamine; 5. phosphoethanolamine; 6. selenium and 7. transferrin; h. An antibiotic and/or antimycotic in the range of 0.1μg/ml to 1 mg/ml selected from the group of: 1. amphotericin-B; 2. gentamycin sulfate; 3. kanamycin sulfate; 4. neomycin sulfate; 5. nystatin; 6. penicillin; 7. tobramycin; and 8. streptomycin; i. ATP presursors in a range of 0.001 mM to 10 mM selected from the group of: 1. adenosine; 2. inosine; and 3. adenine; j. Nutrient cell supplements in a range of 0.001 mM to 10 mM selected from the group of: 1. cholestrol; 2. L-hydroxyproline;

Claim 11

d-biotin; 4. calciferol; 5. niacin; 6. para-aminobenzoic acid; 7. pyridoxine HCl; 8. vitamin B12; 9. Fe(NO 3 ) 3 ; and 10. non-essential amino acids having improved corneal preservation upon storage as compared to the same composition containing the (g) or (h) or (i) or (j) components.

Claim 12

d-biotin; 4. calciferol; 5. niacin; 6. para-aminobenzoic acid; 7. pyridoxine HCl; 8. vitamin B12; 9. Fe(NO 3 ) 3 ; and 10. non-essential amino acids having improved corneal preservation upon storage as compared to the same composition containing the (g) or (h) or (i) or (j) components.

Claim 13

The defined serumfree medical solution containing components which maintain and enhance the preservation of eye tissues, including human corneal tissues at low temperatures (2° C. to 15° C.) with a physiological pH consisting essentially of effective amounts of: a. An aqueous nutrient and electrolyte solution: 1. Eagle's minimal essential medium (MEM) b. A glycosaminoglycan in the range of 0.01 mg/ml to 100 mg/ml 1. chondroitin sulfate; c. A deturgescent agent in the range of 0.01 mg/ml to 100 mg/ml 1. dextran; d. An energy source in a range of 0.05 mM to 10 mM 1. pyruvate; 2. dextrose; e. A buffer system in a range of 0.1 mM to 100 mM 1. Bicarbonate buffer; and 2. HEPES buffer; f. An antioxidant in a range of 0.001 mM to 10 mM 1. 2-mercaptoethanol; and 2. alpha-tocopherol; g. An antibiotic and/or antimycotic in the range of 0.1 μg/ml to 1 mg/ml 1. gentamycin sulfate; h. ATP presursors in a range of 0.001 mM to 10 mM

Claim 14

The defined serumfree medical solution containing components which maintain and enhance the preservation of eye tissues, including human corneal tissues at low temperatures (2° C. to 15° C.) with a physiological pH consisting essentially of effective amounts of: a. An aqueous nutrient and electrolyte solution: 1. Eagle's minimal essential medium (MEM) b. A glycosaminoglycan in the range of 0.01 mg/ml to 100 mg/ml 1. chondroitin sulfate; c. A deturgescent agent in the range of 0.01 mg/ml to 100 mg/ml 1. dextran; d. An energy source in a range of 0.05 mM to 10 mM 1. pyruvate; 2. dextrose; e. A buffer system in a range of 0.1 mM to 100 mM 1. Bicarbonate buffer; and 2. HEPES buffer; f. An antioxidant in a range of 0.001 mM to 10 mM 1. 2-mercaptoethanol; and 2. alpha-tocopherol; g. An antibiotic and/or antimycotic in the range of 0.1 μg/ml to 1 mg/ml 1. gentamycin sulfate; h. ATP presursors in a range of 0.001 mM to 10 mM

Claim 15

adenosine; 2. inosine; and 3. adenine; i. Nutrient cell supplements in a range of 0.001 mM to 10 mM 1. cholestrol; 2. L-hydroxyproline; 3. d-biotin; 4. calciferol; 5. niacin; 6. para-aminobenzoic acid; 7. pyridoxine HCl; 8. vitamin B12; 9. Fe(NO 3 ) 3 ; and 10. non-essential amine acids.

Claim 16

adenosine; 2. inosine; and 3. adenine; i. Nutrient cell supplements in a range of 0.001 mM to 10 mM 1. cholestrol; 2. L-hydroxyproline; 3. d-biotin; 4. calciferol; 5. niacin; 6. para-aminobenzoic acid; 7. pyridoxine HCl; 8. vitamin B12; 9. Fe(NO 3 ) 3 ; and 10. non-essential amine acids.

Claim 17

A method for the storage and preservation of corneal tissue, the method comprising bringing the tissue into contact with the solution of claim 1.